Chemotherapy induced thrombocytopenia in pediatric oncology

Critical Reviews in Oncology/Hematology

Volumn 99, Issue , 2016, Pages 299-307

  Tamamyan, Gevorg ^a,d   Danielyan, Samvel ^a   Lambert, Michele P ^b,c  

^a YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Department of Pediatrics ^*  (Armenia)

Author keywords

Chemotherapy associated thrombocytopenia; Chemotherapy induced thrombocytopenia; CIT; Hypoproliferative thrombocytopenia; IL 11; Pediatric oncology; Platelet transfusion; Thrombopoietin

Indexed keywords

BLEEDING; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED THROMBOCYTOPENIA; CHILD; CHILDHOOD CANCER; COST OF ILLNESS; DISEASE ASSOCIATION; DISEASE SEVERITY; HEALTH CARE COST; HUMAN; INCIDENCE; INVASIVE PROCEDURE; OUTCOME ASSESSMENT; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADULT; CHEMICALLY INDUCED; NEOPLASMS;

ANTINEOPLASTIC AGENT;

ADULT; ANTINEOPLASTIC AGENTS; CHILD; HUMANS; NEOPLASMS; THROMBOCYTOPENIA;

EID: 84959453290     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.01.005     Document Type: Review

References (125)

1. Angiolillo A.L., Davenport V., Bonilla M.A., et al. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group. Clin. Cancer Res. 2005, 11(7):2644-2650. 10.1158/1078-0432.CCR-04-1959.
2. Anon., 2007. Hospira Healthcare Corporation, June 4, 2007. Dacarbazine for injection, BP. 1-27. (accessed 21.10.14.). http://www.hospira.ca/english/_docs/Dacarbazine_Inj_eng.pdf.
3. Anon., 2007. BC Cancer Agency Cancer Drug Manual: Revision March 2007. Mercaptopurine; 1-6. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/55429F79-3CC4-46F3-B76D-291491A181A2/52911/mercaptopurinemonograph_1Mar07.pdf.
4. Anon., 2007. BC Cancer Agency Cancer Drug Manual: Revision March, 2007. Thioguanine; 2-5. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/A4FE5E42-FF68-4151-A8AF-88B30736D368/52916/thioguaninemonograph_1Mar07.pdf.
5. Anon., 2008. BC Cancer Agency Cancer Drug Manual: Revision 1 March, 2008. Vinblastine 1-8. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/D49C56F9-909E-449B-979A-93B285503B50/52932/Vinblastinemonograph_1Mar08newpolicy.pdf.
6. Anon., 2008. BC Cancer Agency Cancer Drug Manual: Revision 1 March 2008. Vincristine; 1-9. (accessed 21.10.14.).
7. Anon., 2010. BC Cancer Agency Cancer Drug Manual: Revision 1 June, 2010. Ifosfamide; 2-8. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/99F10213-E336-4472-826A-164EEAA5B725/45488/Ifosfamidemonograph_1June2010_formatted.pdf.
8. Anon., 2010. The C17 Guidelines. Guideline for Platelet Transfusion Thresholds for Pediatric Hematology/Oncology Patients. http://www.c17.ca.
9. Anon., 2012. Boehringer-Ingelheim: Etoposide. October 2012. (accessed 21.10.14.). http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser%3FdocBase=renetnt%26folderPath=/Prescribing+Information/PIs/Ben+Venue_Bedford+Labs/55390-293-01+ETP+1G/5539029301.
10. Anon., 2013. Daunorubicin Core Safety Profile: Austria, March 2013; 1-8. (accessed 21.10.14.). http://https://www.lakemedelsverket.se/PageFiles/27910/2013/PSURWS/CSPDaunorubicin.pdf.
11. Anon., 2013. BC Cancer Agency Cancer Drug Manual: Revision 1 September, 2013. Methotrexate; 1-16. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/E2FD12F0-1A17-4E30-9975-E436EE980F45/66017/Methotrexate_monograph_1Sept2013_formatted.pdf.
12. Anon., 2014. NCI Common Terminology Criteria for Adverse Events v3.0. (accessed 24.06.14.). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
13. Anon., 2014. The 2011 National Blood Collection and Utilization Survey Report. (accessed 25.10.14.). http://www.hhs.gov/ash/bloodsafety/2011-nbcus.pdf.
14. Anon., 2014. BC Cancer Agency Cancer Drug Manual: Revision 1 June, 2013. Asparaginase; 1-9. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/29039101-BBF2-45CB-A21A-EC4293A76585/64262/Asparaginasemonograph_1June2013_formatted.pdf.
15. Anon., 2014. BC Cancer Agency Cancer Drug Manual: Revision 1 June, 2013. Bleomycin; 1-11. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/7D172F85-5705-4D07-9941-44A88120E52D/64264/Bleomycin_monograph_1June2013_formatted.pdf.
16. Anon., 2014. BC Cancer Agency Cancer Drug Manual: Revision 1 January, 2014. Carboplatin; 1-9. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/31E5B9AC-782D-4942-BC31-CA2B0012F3CA/67832/Carboplatinmonograph_1Jan2014.pdf.
17. Anon., 2014. BC Cancer Agency Cancer Drug Manual: Revision 1 June, 2013. Cisplatin; 1-11. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/DCC88F7E-EDF8-4340-A63A-932144D9E282/64270/Cisplatin_monograph_1June2013_formatted.pdf.
18. Anon., 2014. BC Cancer Agency Cancer Drug Manual: Revision 1 June, 2013. Cyclophosphamide; 1-12. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/37BE9D9E-8E5A-48C2-ABA1-953637C4A5C0/64273/Cyclophosphamide_monograph_1June2013_formatted.pdf.
19. Anon., 2014. BC Cancer Agency Cancer Drug Manual: Revision 1 May, 2014. Cytarabine; 1-10. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/8EBC42A3-069A-46B1-AAAD-B2450AD63C38/69939/cytarabinemonograph_1May2014.pdf.
20. Anon., 2014. BC Cancer Agency Cancer Drug Manual: Revision 1 September, 2014. Dactinomycin; 1-7. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/852A1FC3-5BD2-481B-BFAA-45ACBFA77FAC/71932/Dactinomycin_monograph_1Sep2014.pdf.
21. Anon., 2014. BC Cancer Agency Cancer Drug Manual: Revision 1 October, 2014. Daunorubicin; 1-7. (accessed 21.10.14.). http://www.bccancer.bc.ca/NR/rdonlyres/74387BC6-E514-4BBC-9D0F-7AD044B0D287/72661/Daunorubicin_monograph_1Oct2014.pdf.
22. Anon., 2014. Pfizer New Zealand-Adriamycin: 30 May, 2014. 1-14. (accessed 21.10.14.). http://www.medsafe.govt.nz/profs/datasheet/a/adriamycininj.pdf.
23. Aribi A., Kantarjian H., Koller C., et al. The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2008, 113(6):1338-1343. 10.1002/cncr.23718.
24. Avanzi M.P., Mitchell W.B. Ex vivo production of platelets from stem cells. Br. J. Haematol. 2014, 165(2):237-247. 10.1111/bjh.12764.
25. Bürger B., Zimmermann M., Mann G., et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J. Clin. Oncol. 2003, 21(2):184-188.
26. Benjamin R.J., Anderson K.C. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?. Crit. Rev. Oncol. Hematol. 2002, 42(2):163-171.
27. Benjamin R.J., Antin J.H. ABO-incompatible bone marrow transplantation the transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion 2016, 39(11-12):1273-1274. (accessed 24.10.14.).
28. Bercovitz R.S., Josephson C.D. Thrombocytopenia and bleeding in pediatric oncology patients. Hematol. Am. Soc. Hematol. Educ. Program 2012, 2012:499-505. 10.1182/asheducation-2012.1.499.
29. Bercovitz R.S., O'Brien S.H. Measuring bleeding as an outcome in clinical trials of prophylactic platelet transfusions. Hematol. Am. Soc. Hematol. Educ. Program 2012, 2012:157-160. 10.1182/asheducation-2012.1.157.
30. Berthelot-Richer M., Boilard B., Morin A., Bolduc B., Beauregard P., Kotb R. Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. Transfusion 2012, 52(4):739-741. 10.1111/j.1537-2995.2011.03382.x.
31. Bhatia M., Davenport V., Cairo M.S. The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. Leuk. Lymphoma 2007, 48(1):9-15. 10.1080/10428190600909115.
32. Blajchman M.a., Slichter S.J., Heddle N.M., Murphy M.F. New strategies for the optimal use of platelet transfusions. Hematol. Am. Soc. Hematol. Educ. Program 2008, 198-204. 10.1182/asheducation-2008.1.198.
33. Blumberg N., Heal J.M., Liesveld J.L., Phillips G.L., Rowe J.M. Platelet transfusion and survival in adults with acute leukemia. Leukemia 2008, 22(3):631-635. 10.1038/sj.leu.2404920.
34. Blumberg N., Heal J.M., Phillips G.L., Phipps R.P. Platelets-to transfuse or not to transfuse. Lancet 2012, 380(9850):1287-1289. 10.1016/S0140-6736(12) 60983-0.
35. Boggs D.R., Wintrobe M.M., Cartwright G.E. The acute leukemias. Analysis of 322 cases and review of the literature. Medicine (Baltimore) 1962, 41:163-225. (accessed 25.10.14.).
36. Cameron B., Rock G., Olberg B., Neurath D. Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion 2007, 47(2):206-211. 10.1111/j.1537-2995.2007.01090.x.
37. Ceppi F., Antillon F., Pacheco C., et al. Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries. Exp. Rev. Hematol. 2015, 8(5):613-626. 10.1586/17474086.2015.1049594.
38. Cosmi B., Alatri A., Cattaneo M., et al. Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb. Res. 2009, 124(5):e6-e12. 10.1016/j.thromres.2009.08.005.
39. Diedrich B., Remberger M., Shanwell A., Svahn B.-M., Ringdén O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10×10(9) per L versus 30×10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005, 45(7):1064-1072. 10.1111/j.1537-2995.2005.04157.x.
40. Drozd-Sokolowska J.E., Wiktor-Jedrzejczak W. Factors determining the risk of severe (WHO grades 3 and 4) hemorrhage in hematologic patients. Transfus. Apheresis Sci. 2011, 44(2):129-134. 10.1016/j.transci.2011.01.004.
41. Egberts T.G. Thrombocytopenia in Adult Cancer Patients Receiving Cytotoxic Chemotherapy. 2011.
42. Eikenboom J.C.J., van Wordragen R., Brand A. Compliance with prophylactic platelet transfusion trigger in haematological patients. Transfus. Med. 2005, 15(1):45-48. 10.1111/j.1365-3148.2005.00547.x.
43. Elting B.L.S., Rubenstein E.B., Martin C.G., et al. Patients with chemotherapy-induced thrombocytopenia 2001, 19(4):1137-1146.
44. Elting L.S., Rubenstein E.B., Martin C.G., et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J. Clin. Oncol. 2001, 19(4):1137-1146. (accessed 15.10.14.).
45. Estcourt L.J., Stanworth S.J., Murphy M.F. Prophylactic platelet transfusions. Curr. Opin. Hematol. 2010, 17(5):411-417. 10.1097/MOH.0b013e32833c07e8.
46. Estcourt L.J., Birchall J., Lowe D., Grant-Casey J., Rowley M., Murphy M.F. Platelet transfusions in haematology patients: are we using them appropriately?. Vox Sang. 2012, 103(4):284-293. 10.1111/j.1423-0410.2012.01627.x.
47. Fanucchi M., Glaspy J., Crawford J., et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N. Engl. J. Med. 1997, 336(6):404-409. 10.1056/NEJM199702063360603.
48. Fuentes R., Wang Y., Hirsch J., et al. Infusion of mature megakaryocytes into mice yields functional platelets. J. Clin. Invest. 2010, 120(11):3917-3922. 10.1172/JCI43326.
49. Gajjar A., Harrison P.L., Sandlund J.T., et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 2000, 96(10):3381-3384.
50. Gantt C.L. Red blood cells for cancer patients. Lancet 1981, 2(8242):363. (accessed 24.10.14.).
51. Gaydos L.A., Freireich E.J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N. Engl. J. Med. 1962, 266:905-909. 10.1056/NEJM196205032661802.
52. Giannini E.G., Greco A., Marenco S., Andorno E., Valente U., Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin. Gastroenterol. Hepatol. 2010, 8(10):899-902. quiz e109. 10.1016/j.cgh.2010.06.018.
53. Goldberg G.L., Gibbon D.G., Smith H.O., DeVictoria C., Runowicz C.D., Burns E.R. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J. Clin. Oncol. 1994, 12(11):2317-2320.
54. Greeno E., McCullough J., Weisdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion 2007, 47(2):201-205. 10.1111/j.1537-2995.2007.01089.x.
55. Hainsworth J.D., Greco F.A. Etoposide: twenty years later. Ann. Oncol. 1995, 6(4):325-341. (accessed 21.10.14.).
56. Heckman K.D., Weiner G.J., Davis C.S., Strauss R.G., Jones M.P., Burns C.P. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J. Clin. Oncol. 2014, (accessed 15.10.14.).
57. Hirschfeld S., Ho P.T.C., Smith M., Pazdur R. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J. Clin. Oncol. 2003, 21(6):1066-1073. 10.1200/JCO.2003.11.138.
58. Hitron A., Steinke D., Sutphin S., Lawson A., Talbert J., Adams V. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J. Oncol. Pharm. Pract. 2011, 17(4):312-319. 10.1177/1078155210380293.
59. Hollý P., Lisá L., Plameňová I., Dobrotová M., Kubisz P. Recombinant activated factor VII as an additional agent in the management of bleeding in patients with chemotherapy-induced thrombocytopenia. Blood Transfus. 2013, 11(3):466-468. 10.2450/2012.0077-12.
60. Howard S.C., Gajjar A.J., Cheng C., et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA 2016, 288(16):2001-2007.
61. Hunger S.P., Sung L., Howard S.C. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: a proposal. Pediatr. Blood Cancer. 2009, 52(5):559-565. 10.1002/pbc.21889.
62. Jardim D.L., Rodrigues C.a., Novis Y.a.S., Rocha V.G., Hoff P.M. Oxaliplatin-related thrombocytopenia. Ann. Oncol. 2012, 23(8):1937-1942. 10.1093/annonc/mds074.
63. Josephson C.D., Granger S., Assmann S.F., et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 2012, 120(4):748-760. 10.1182/blood-2011-11-389569.
64. Kantarjian H., Giles F., List A., et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007, 109(9):1705-1714. 10.1002/cncr.22602.
65. Kantarjian H., Fenaux P., Sekeres M.A., et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J. Clin. Oncol. 2010, 28(3):437-444. 10.1200/JCO.2009.24.7999.
66. Kaushansky K. The thrombocytopenia of cancer. Prospects for effective cytokine therapy. Hematol. Oncol. Clin. North Am. 1996, 10(2):431-455. (accessed 15.10.14.).
67. Khorana A.A., Francis C.W., Blumberg N., Culakova E., Refaai M.A., Lyman G.H. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch. Intern. Med. 2008, 168(21):2377-2381. 10.1001/archinte.168.21.2377.
68. Kiefel V. Reactions induced by platelet transfusions. Transfus. Med. Hemother. 2008, 35(5):354-358. 10.1159/000151350.
69. Kim E.-J., Lim K.-M., Kim K.-Y., et al. Doxorubicin-induced platelet cytotoxicity: a new contributory factor for doxorubicin-mediated thrombocytopenia. J. Thromb. Haemost. 2009, 7(7):1172-1183. 10.1111/j.1538-7836.2009.03477.x.
70. Kleinman S., Chan P., Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus. Med. Rev. 2003, 17(2):120-162. 10.1053/tmrv.2003.50009.
71. Kuter, D.J., 2014. Clinical applications of thrombopoietic growth factors. Uptodate 2014. http://www.uptodate.com/contents/clinical-applications-of-thrombopoietic-growth-factors.
72. Lambert M.P., Rauova L., Bailey M., Sola-Visner M.C., Kowalska M.A., Poncz M. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood 2007, 110(4):1153-1160. 10.1182/blood-2007-01-067116.
73. Lambert M.P., Sullivan S.K., Fuentes R., French D.L., Poncz M. Challenges and promises for the development of donor-independent platelet transfusions. Blood 2013, 121(17):3319-3324. 10.1182/blood-2012-09-455428.
74. Levin R.D., Daehler M., Grutsch J.F., Hall J.L., Gupta D., Lis C.G. Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. BMC Cancer 2010, 10:565. 10.1186/1471-2407-10-565.
75. Lieberman L., Liu Y., Portwine C., Barty R.L., Heddle N.M. An epidemiologic cohort study reviewing the practice of blood product transfusions among a population of pediatric oncology patients. Transfusion 2014, 54(Pt. 2 (10)):2736-2744. 10.1111/trf.12677.
76. Lin Y., Foltz L.M. Proposed guidelines for platelet transfusion. BC Med. J. 2005, 47(5):245-248.
77. Liou S.Y., Stephens J.M., Carpiuc K.T., Feng W., Botteman M.F. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin. Drug Investig. 2007, 27(6):381-396. (accessed 16.06.14.).
78. Liumbruno G., Bennardello F., Lattanzio A., Piccoli P., Rossetti G. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009, 7(2):132-150. 10.2450/2009.0005-09.
79. Lonial S., Waller E.K., Richardson P.G., et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106(12):3777-3784. 10.1182/blood-2005-03-1173.
80. Lu S.-J., Li F., Yin H., et al. Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. Cell Res. 2011, 21(3):530-545.
81. Matsunaga T., Tanaka I., Kobune M., et al. Ex vivo large-scale generation of human platelets from cord blood CD34+ cells. Stem Cells 2006, 24(12):2877-2887. 10.1634/stemcells.2006-0309.
82. Mehta P.S., Wiernikowski J.T., Petrilli J.A.S., Barr R.D. Essential medicines for pediatric oncology in developing countries. Pediatr. Blood Cancer 2013, 60(5):889-891. 10.1002/pbc.24476.
83. Pediatric Hematology/Oncology Ward Officer's Handbook 2010, Baylor College of Medicine, Houston, TX. P.S. Mehta (Ed.).
84. Moskowitz C.H., Hamlin P.A., Gabrilove J., et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann. Oncol. 2007, 18(11):1842-1850. 10.1093/annonc/mdm341.
85. Mulcahy N. Do blood cancers need prophylactic platelet transfusions?. Medscape Med. News 2013, http://www.medscape.com/viewarticle/803787.
86. Murphy S., Litwin S., Herring L.M., et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982, 12(4):347-356. (accessed 15.10.14.).
87. Newland A.C. The problem of thrombocytopenia and its management. Anticancer Drugs 1995, 6(Suppl. 5):65-73. (accessed 25.10.14.).
88. OBrien S.F., Yi Q.-L., Fan W., Scalia V., Kleinman S.H., Vamvakas E.C. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007, 47(2):316-325. 10.1111/j.1537-2995.2007.01108.x.
89. Oshima Y., Yuji K., Tanimoto T., Hinomura Y., Tojo A. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. Intern. Med. 2013, 52(19):2193-2201. (accessed 22.10.14.).
90. Parameswaran R., Lunning M., Mantha S., et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer 2014, 22(5):1217-1222. 10.1007/s00520-013-2074-2.
91. Parker R.I. Transfusion in critically ill children: indications, risks, and challenges. Crit. Care Med. 2014, 42(3):675-690. 10.1097/CCM.0000000000000176.
92. Pisciotto P.T., Benson K., Hume H., et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995, 35(6):498-502.
93. Prica A., Sholzberg M., Buckstein R. Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials. Br. J. Haematol. 2014, 10.1111/bjh.13088.
94. Qureshi H., Lowe D., Dobson P., et al. National comparative audit of the use of platelet transfusions in the UK. Transfus. Clin. Biol. 2007, 14(6):509-513. 10.1016/j.tracli.2008.01.002.
95. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N. Engl. J. Med. 1997, 337(26):1870-1875. 10.1056/NEJM199712253372602.
96. Reems J.-A., Pineault N., Sun S. In vitro megakaryocyte production and platelet biogenesis: state of the art. Transfus. Med. Rev. 2010, 24(1):33-43. 10.1016/j.tmrv.2009.09.003.
97. Roy A.J., Jaffe N., Djerassi I. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 2016, 13(5):283-290.
98. Savarese D.M., Hsieh C., Stewart F.M. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J. Clin. Oncol. 1997, 15(8):2981-2995. (accessed 18.10.14.).
99. Schiffer C.a., Anderson K.C., Bennett C.L., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 2001, 19(5):1519-1538.
100. Sekhon S.S., Roy V. Thrombocytopenia in adults: a practical approach to evaluation and management. South. Med. J. 2006, 99(5):491-498.
101. Shaikh F., Voicu L., Tole S., et al. The risk of traumatic lumbar punctures in children with acute lymphoblastic leukaemia. Eur. J. Cancer 2014, 50(8):1482-1489. 10.1016/j.ejca.2014.02.021.
102. Shu L.-L., Jiang Q.-L., Meng F.-Y., Yang M. Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011, 19(5):1314-1318. (accessed 15.10.14.).
103. Slichter S.J., Harker L.A. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin. Haematol. 1978, 7(3):523-539. (accessed 15.10.14.).
104. Slichter S.J. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus. Med. Rev. 2004, 18(3):153-167. (accessed 18.10.14.).
105. Slichter S.J. Evidence-based platelet transfusion guidelines. Hematol. Am. Soc. Hematol. Educ. Program 2007, 172-178. 10.1182/asheducation-2007.1.172.
106. Stanworth S.J., Dyer C., Choo L., et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet t. Transfus. Med. Rev. 2010, 24(3):163-171. 10.1016/j.tmrv.2009.11.002.
107. Stanworth S.J., Estcourt L.J., Powter G., et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N. Engl. J. Med. 2013, 368(19):1771-1780. 10.1056/NEJMoa1212772.
108. Stroncek D.F., Rebulla P. Platelet transfusions. Lancet 2007, 370(9585):427-438. 10.1016/S0140-6736(07) 61198-2.
109. Takayama N., Eto K. Pluripotent stem cells reveal the developmental biology of human megakaryocytes and provide a source of platelets for clinical application. Cell. Mol. Life Sci. 2012, 69(20):3419-3428. 10.1007/s00018-012-0995-4.
110. Te Loo D.M.W.M., Kamps W.a., van der Does-van den Berg A., van Wering E.R., de Graaf S.S.N. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. J. Clin. Oncol. 2006, 24(15):2332-2336. 10.1200/JCO.2005.03.9727.
111. Tosetto A., Balduini C.L., Cattaneo M., et al. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb. Res. 2009, 124(5):e13-e18. 10.1016/j.thromres.2009.06.009.
112. Vadhan-Raj S., Verschraegen C.F., Bueso-Ramos C., et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann. Intern. Med. 2000, 132(5):364-368.
113. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin. Hematol. 2009, 46(Suppl. 2):S26-S32. 10.1053/j.seminhematol.2008.12.007.
114. Vamvakas E.C. Allogeneic blood transfusion and cancer recurrence: 20 years later. Transfusion 2014, 54(9):2149-2153. 10.1111/trf.12689.
115. WHO Handbook for Reporting Results of Cancer Treatment 1979, World Health Organization, Geneva.
116. WHO Model List of Essential Medications. 18th list. April 2013.
117. Wandt H., Schaefer-Eckart K., Wendelin K., et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012, 380(9850):1309-1316. 10.1016/S0140-6736(12) 60689-8.
118. Wandt H. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist 2001, 6(5):446-450. 10.1634/theoncologist.6-5-446.
119. Webb I.J., Anderson K.C. Risks, costs, and alternatives to platelet transfusions. Leuk. Lymphoma 1999, 34(1-2):71-84. 10.3109/10428199909083382.
120. Webert K.E., Arnold D.M., Carruthers Lui Y, Arnold J., Heddle E. A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia. Transfusion 2012, 52(11):2466-2474. quiz 2465. 10.1111/j. 1537-2995.2012.03634.x.
121. Werth Jih DM Thrombocytopenia after a single test dose of methotrexate. J. Am. Acad. Dermatol. 1998, 39(Pt. 2):349-351. (accessed 21.10.14.).
122. Wu Y., Aravind S., Ranganathan G., Martin A., Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin. Ther. 2009, 31(Pt. 2):2416-2432. 10.1016/j.clinthera.2009.11.020.
123. Zeidler K., Arn K., Senn O., Schanz U., Stussi G. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion 2011, 51(11):2269-2276. 10.1111/j.1537-2995.2011.03147.x.
124. Zhang Wu S, et al. Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy. Support Care Cancer 2012, 20(8):1875-1884. 10.1007/s00520-011-1290-x.
125. Zumberg M.S., del Rosario M.L.U., Nejame C.F., et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol. Blood Marrow Transplant 2002, 8(10):569-576. (accessed 15.10.14.).